 Shares of Osmotica Pharmaceuticals NASDAQ:OSMT decreased 4.46 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 650.00 year over year to 0.22, which missed the estimate of 0.12.Revenue of 37,532,000 declined by 34.76 from the same period last year, which missed the estimate of 40,830,000.Guidance Earnings guidance hasnt been issued by the company for now.Osmotica Pharmaceuticals hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 11, 2020View more earnings on OSMTTime: 04:30 PMET Webcast URL: Companys 52-week high was at 9.6752-week low: 2.70Price action over last quarter: Up 39.90Company Overview Osmotica Pharmaceuticals PLC is a fully-integrated biopharmaceutical company. It is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and womens health products, which are primarily complex formulations of generic drugs. Osmotica has a late?stage development pipeline by two NDA candidates that recently completed Phase III clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVL?1201 for the treatment of acquired blepharoptosis, or droopy eyelid.See more from Benzinga Earnings Scheduled For August 11, 2020 18 Healthcare Stocks Moving In Thursdays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 